Effect of tea polyphenol compounds on anticancer drugs in terms of anti-tumor activity, toxicology, and pharmacokinetics

Nutrients

Volumn 8, Issue 12, 2016, Pages

  Cao, Jianhua ^a   Han, Jie ^a   Xiao, Hao ^a   Qiao, Jinping ^a   Han, Mei ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

Author keywords

Anticancer agent; Pharmacokinetics; Synergistic anticancer activity; Tea polyphenol; Toxicology

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; CAFFEINE; CATECHIN; CELECOXIB; CISPLATIN; CURCUMIN; DOCETAXEL; DOXORUBICIN; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; GALLIC ACID; IBUPROFEN; LUTEOLIN; PACLITAXEL; POLYPHENOL DERIVATIVE; QUERCETIN; RESVERATROL; SINECATECHINS; SULFORAPHANE; SUNITINIB; TAMOXIFEN; TEA POLYPHENOL; UNCLASSIFIED DRUG; VINBLASTINE; POLYPHENOL; TEA;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME ABERRATION; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TEA; TUMOR RESISTANCE; TUMOR VOLUME; UTERINE CERVIX CANCER; CHEMISTRY; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATECHIN; DRUG SYNERGISM; HUMANS; NEOPLASMS; POLYPHENOLS; TEA;

EID: 85006761786     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8120762     Document Type: Review

References (62)

1. Qiao, J., Kong, X., Kong, A., Han, M. Pharmacokinetics and biotransformation of tea polyphenols. Curr. Drug Metab. 2014, 15, 30–36.
2. Fujiki, H., Suganuma, M., Imai, K., Nakachi, K. Green tea: Cancer preventive beverage and/or drug. Cancer Lett. 2002, 188, 9–13.
3. Afzal, M., Safer, A.M., Menon, M. Green tea polyphenols and their potential role in health and disease. Inflammopharmacology 2015, 23, 151–161.
4. Hara, Y. Tea catechins and their applications as supplements and pharmaceutics. Pharmacol. Res. 2011, 64, 100–104.
5. Fujiki, H. Green tea: Health benefits as cancer preventive for humans. Chem. Rec. 2005, 5, 119–132.
6. Lambert, J.D., Yang, C.S. Mechanisms of cancer prevention by tea constituents. J. Nutr. 2003, 133, 3262S–3267S.
7. Higdon, J.V., Frei, B. Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci. Nutr. 2003, 43, 89–143.
8. Yang, C.S., Maliakal, P., Meng, X. Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 25–54.
9. Fujiki, H., Imai, K., Nakachi, K., Shimizu, M., Moriwaki, H., Suganuma, M. Challenging the effectiveness of green tea in primary and tertiary cancer prevention. J. Cancer Res. Clin. Oncol. 2012, 138, 1259–1270.
10. Alshatwi, A.A., Periasamy, V.S., Athinarayanan, J., Elango, R. Synergistic anticancer activity of dietary tea polyphenols and bleomycin hydrochloride in human cervicalcancer cell: Caspase-dependent and independent apoptotic pathways. Chem. Biol. Interact. 2016, 247, 1–10.
11. Suganuma, M., Saha, A., Fujiki, H. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci. 2011, 102, 317–323.
12. Morre, D.J., Morre, D.M., Sun, H., Cooper, R., Chang, J., Janle, E.M. Tea catechin synergies in inhibition of cancer cell proliferation and of a cancer specific cell surface oxidase (ECTO-NOX). Pharmacol. Toxicol. 2003, 92, 234–241.
13. Fujiki, H., Sueoka, E., Watanabe, T., Suganuma, M. Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with thecombination of EGCG, other green tea catechins, and anticancer compounds. J. Cancer Res. Clin. Oncol. 2015, 141, 1511–1522.
14. Adhami, V.M., Malik, A., Zaman, N., Sarfaraz, S., Siddiqui, I.A., Syed, D.N., Afaq, F., Pasha, F.S., Saleem, M., Mukhtar, H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 2007, 13, 1611–1619.
15. Qiao, J., Gu, C., Shang, W., Du, J., Yin, W., Zhu, M., Wang, W., Han, M., Lu, W. Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. Food Chem. Toxicol. 2011, 49, 1410–1415.
16. Sriram, N., Kalayarasan, S., Sudhandiran, G. Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis. Chem. Biol. Interact. 2009, 180, 271–280.
17. Periasamy, V.S., Alshatwi, A.A. Tea polyphenols modulate antioxidant redox system on cisplatin-induced reactive oxygen species generation in a human breast cancer cell. Basic Clin. Pharmacol. Toxicol. 2013, 112, 374–384.
18. Chen, S.Z., Zhen, Y.S. Molecular targets of tea polyphenols and its roles of anticancer drugs in experimental therapy. Yao Xue Xue Bao 2013, 48, 1–7.
19. Ahmad, K.A., Harris, N.H., Johnson, A.D., Lindvall, H.C., Wang, G., Ahmed, K. Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol. Cancer Ther. 2007, 6, 1006–1012.
20. Mazumder, M.E., Beale, P., Chan, C., Yu, J.Q., Huq, F. Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells. Anticancer Res. 2012, 32, 4851–4860.
21. Chan, M.M., Soprano, K.J., Einstein, K., Fong, D. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhancestheir cisplatin susceptibility. J. Cell Physiol. 2006, 207, 389–396.
22. Chan, M.M., Fong, D., Soprano, K.J., Holmes, W.F., Heverling, H. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J. Cell Physiol. 2003, 194, 63–70.
23. Kim, M.H., Chung, J. Synergistic cell death by EGCG and ibuprofen in DU-145 prostate cancer cell line. Anticancer Res. 2007, 27, 3947–3956.
24. Farabegoli, F., Papi, A., Orlandi, M. (α)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci. Rep. 2011, 31, 99–108.
25. Scandlyn, M.J., Stuart, E.C., Somers-Edgar, T.J., Menzies, A.R., Rosengren, R.J. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br. J. Cancer 2008, 99, 1056–1063.
26. Chisholm, K., Bray, B.J., Rosengren, R.J. Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs 2004, 15, 889–897.
27. Suganuma, M., Okabe, S., Kai, Y., Sueoka, N., Sueoka, E., Fujiki, H. Synergistic effects of -epigallocatechin gallate with (α)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res. 1999, 59, 44–47.
28. Fujiki, H., Suganuma, M., Kurusu, M., Okabe, S., Imayoshi, Y., Taniguchi, S., Yoshida, T. New TNF- releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. Mutat. Res. 2003, 524, 119–125.
29. Bannerman, B., Xu, L., Jones, M., Tsu, C., Yu, J., Hales, P., Monbaliu, J., Fleming, P., Dick, L., Manfredi, M., et al. Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother. Pharmacol. 2011, 68, 1145–1154.
30. Golden, E.B., Lam, P.Y., Kardosh, A., Kardosh, A., Gaffney, K.J., Cadenas, E., Louie, S.G., Petasis, N.A., Chen, T.C., Schönthal, A.H. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113, 5927–5937.
31. Glynn, S.J., Gaffney, K.J., Sainz, M.A., Louie, S.G., Petasis, N.A. Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols. Org. Biomol. Chem. 2015, 13, 3887–3899.
32. Suganuma, M., Kurusu, M., Suzuki, K., Tasaki, E., Fujiki, H. Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene. Int. J. Cancer 2006, 119, 33–40.
33. Amin, A.R., Wang, D., Zhang, H., Peng, S., Shin, H.J., Brandes, J.C., Tighiouart, M., Khuri, F.R., Chen, Z.G., Shin, D.M. Enhanced anti-tumor activity by the combination of the natural compounds (α)-epigallocatechin-3-gallate and luteolin: Potential role of p53. J. Biol. Chem. 2010, 285, 34557–34565.
34. Chen, H., Landen, C.N., Li, Y., Alvarez, R.D., Tollefsbol, T.O. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp. Cell Res. 2013, 319, 697–706.
35. Yang, X.W., Wang, X.L., Cao, L.Q., Jiang, X.F., Peng, H.P., Lin, S.M., Xue, P., Chen, D. Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells. Hepatol. Res. 2012, 42, 494–501.
36. Saha, A., Kuzuhara, T., Echigo, N., Suganuma, M., Fujiki, H. New role of (α)-epicatechin in enhancing the induction of growth inhibition and apoptosis in human lung cancer cells by curcumin. Cancer Prev. Res. 2010, 3, 953–962.
37. Ghosh, A.K., Kay, N.E., Secreto, C.R., Shanafelt, T.D. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin. Cancer Res. 2009, 15, 1250–1258.
38. Somers-Edgar, T.J., Scandlyn, M.J., Stuart, E.C., Le Nedelec, M.J., Valentine, S.P., Rosengren, R.J. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo. Int. J. Cancer 2008, 122, 1966–1971.
39. Tang, S.N., Singh, C., Nall, D., Meeker, D., Shankar, S., Srivastava, R.K. The dietary bioflavonoid quercetin synergizes with epigallocatechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J. Mol. Signal. 2010, 5, 14.
40. Hsieh, T.C., Wu, J.M. Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res. 2009, 29, 4025–4032.
41. Stearns, M.E., Wang, M. Synergistic effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors. Transl. Oncol. 2011, 4, 147–156.
42. Liang, G., Tang, A., Lin, X., Li, L., Zhang, S., Huang, Z., Tang, H., Li, Q.Q. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int. J. Oncol. 2010, 37, 111–123.
43. Hsieh, T.C., Wu, J.M. Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. Int. J. Oncol. 2008, 33, 851–859.
44. Nair, S., Hebbar, V., Shen, G., Gopalakrishnan, A., Khor, T.O., Yu, S., Xu, C., Kong, A.N. Synergistic effects of a combination of dietary factors sulforaphane and (α)-epigallocatechin-3-gallate in HT-29 AP-1 human colon carcinoma cells. Pharm. Res. 2008, 25, 387–399.
45. Wang, G., Bhoopalan, V., Wang, D., Wang, L., Xu, X. The effect of caffeine on cisplatin-induced apoptosis of lung cancer cells. Exp. Hematol. Oncol. 2015, 4.
46. Tsuchiya, H., Mori, Y., Ueda, Y., Okada, G., Tomita, K. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res. 2000, 20, 235–242.
47. Karita, M., Tsuchiya, H., Kawahara, M., Kasaoka, S., Tomita, K. The antitumor effect of liposome-encapsulated cisplatin on rat osteosarcoma and its enhancement by caffeine. Anticancer Res. 2008, 28, 1449–1457.
48. Geriyol, P., Basavanneppa, H.B., Dhananjaya, B.L. Protecting effect of caffeine against vinblastine (an anticancer drug) induced genotoxicity in mice. Drug Chem. Toxicol. 2015, 38, 188–195.
49. Dudka, J., Gieroba, R., Korga, A., Burdan, F., Matysiak, W., Jodlowska-Jedrych, B., Mandziuk, S., Korobowicz, E., Murias, M. Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Evid.-Based Complement. Altern. Med. 2012, 2012, 606183.
50. Chari, N.S., Pinaire, N.L., Thorpe, L., Medeiros, L.J., Routbort, M.J., McDonnell, T.J. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis 2009, 14, 336–347.
51. Weijl, N.I., Elsendoorn, T.J., Lentjes, E.G., Hopman, G.D., Wipkink-Bakker, A., Zwinderman, A.H. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: A randomised, double-blind, placebo-controlled study. Eur. J. Cancer 2004, 40, 1713–1723.
52. Li, W., Nie, S., Xie, M., Chen, Y., Li, C., Zhang, H. A major green tea component, (α)-epigallocatechin-3-gallate ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal rats. J. Agric. Food Chem. 2010, 58, 8877.
53. Khan, G., Haque, S.E., Anwer, T., Ahsan, M.N., Safhi, M.M., Alam, M.F. Cardioprotective effect of green tea extract on doxorubicin-induced cardiotoxicity in rats. Acta Pol. Pharm. 2014, 71, 861–867.
54. Saeed, N.M., El-Naga, R.N., El-Bakly, W.M., Abdel-Rahman, H.M., Salah El-Din, R.A., El-Demerdash, E. Epigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: A mechanistic study. Biochem. Pharmacol. 2015, 95, 145–155.
55. Fleisher, B., Unum, J., Shao, J., An, G. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: A new mechanism of beverage-drug interaction. J. Pharm. Sci. 2015, 104, 266–275.
56. Knop, J., Misaka, S., Singer, K., Hoier, E., Müller, F., Glaeser, H., König, J., Fromm, M.F. Inhibitory Effects of Green Tea and (±)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS ONE 2015, 10, e0139370.
57. Shang, W., Lu, W., Han, M., Qiao, J. The interactions of anticancer agents with tea catechins: Current evidence from preclinical studies. Anticancer Agents Med. Chem. 2014, 14, 1343–1450.
58. Mirkov, S., Komoroski, B.J., Ramírez, J., Graber, A.Y., Ratain, M.J., Strom, S.C., Innocenti, F. Effects of green tea compounds on irinotecan metabolism. Drug Metab. Dispos. 2007, 35, 228–233.
59. Zhou, Y., Tang, J., Du, Y., Ding, J., Liu, J.Y. The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells. Tumor Biol. 2016, 5, 1–12.
60. ClinicalTrials gov. Available online: https://clinicaltrials.gov/ (accessed on 26 September 2016).
61. Jonsson Comprehensive Cancer Center. Available online: https://clinicaltrials.gov/ct2/show/NCT00685516 (accessed on 22 May 2008).
62. Henning, S.M., Wang, P., Said, J.W., Huang, M., Grogan, T., Elashoff, D., Carpenter, C.L., Heber, D., Aronson, W.J. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate 2015, 75, 550–559.